5th Berlin Conference on IP in Life Sciences
Antibodies currently dominate the lists of the blockbuster drugs in the pharmaceutical industry. But the large biomolecules have their limitations and are also still very expensive to produce. There is room for new technologies.
Leading experts in drug development, clinical trials and representatives from all major biotech companies met at the 5th annual Berlin Conference which was held on February 17 at the Swiss Embassy to discuss the latest trends in immune therapy development. The conference was organised by the event manager BIOCOM.